Evommune (EVMN) Enterprise Value (2024 - 2026)
Evommune (EVMN) posted quarterly Enterprise Value of -$211.5 million for Q1 2026, down 3607.29% year-over-year from $6.0 million in Q1 2025, and down 41.73% quarter-over-quarter from -$149.2 million in Q4 2025.
Evommune (EVMN) Enterprise Value (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Enterprise Value for 3 consecutive years, with -$211.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 3607.29% year-over-year to -$211.5 million; the TTM figure through Mar 2026 stood at -$211.5 million (down 3607.29% YoY), while the FY2025 annual figure was -$149.2 million, down 107.11% from the prior year.
- Enterprise Value declined to -$211.5 million in Q1 2026 per EVMN's latest filing, from -$149.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$5.7 million in Q1 2025 and bottomed at -$211.5 million in Q1 2026.
- Historically, Enterprise Value has averaged -$88.8 million across 3 years, with a median of -$74.1 million in 2024.
- Annual changes were most pronounced in 2025 — Enterprise Value sank 107.11% — and 2026, when it plunged 3607.29%.
- Evommune's Enterprise Value stood at -$72.0 million in 2024, then tumbled by 107.11% to -$149.2 million in 2025, then slumped by 41.73% to -$211.5 million in 2026.
- Business Quant data shows EVMN's Enterprise Value at -$211.5 million in Q1 2026, -$149.2 million in Q4 2025, and -$76.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | -200.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -200.79 Mn |
| Mar 31, 2026 | -211.46 Mn |
| Dec 31, 2025 | -149.20 Mn |
| Sep 30, 2025 | -76.06 Mn |
| Mar 31, 2025 | -5.70 Mn |
| Dec 31, 2024 | -72.04 Mn |
| Sep 30, 2024 | -18.15 Mn |